January 2018 DAIT Council-Approved Concepts

Concepts represent early planning stages for program announcements, requests for applications, or solicitations for Council's input. If NIAID publishes an initiative from one of these concepts, we link to it below. To find initiatives, go to Opportunities & Announcements.

NB: Council approval does not guarantee that a concept will become an initiative.

Table of Contents

Fiscal Year 2019 Concepts

Fiscal Year 2019 Small Business Innovation Research (SBIR) Contract Solicitation Topics

B Cell Epitope Discovery and Mechanisms of Antibody-Mediated Protection

Broad Agency Announcement—proposed FY 2019 initiative

Contact: Mylinh Pham

Objective: To support basic research aimed at discovering novel B cell epitopes and to elucidate mechanisms of antibody-mediated protective immunity and/or mechanisms of antibody-mediated pathology triggered by infectious agents or vaccines. Data from this program have been used to predict cross-protective epitopes among related pathogens, generate therapeutic antibodies, and inform the development of epitope-based vaccine strategies. While NIAID will continue to support infectious diseases studies, the scope of this program will be expanded to include epitope discovery for antibodies associated with either autoimmune diseases or transplant rejection.

Description: This program will support identifying B cell epitopes, coupled with basic studies to understand protective immunity mediated by antibodies and, when applicable, pathological consequences of antibody responses. Investigators may use recent technological advances for epitope discovery, such as genome-wide scanning, high-throughput single-cell analysis, next generation sequencing technologies, structural genomics and proteomics, or developing new or improved technologies, including computer-based B cell epitope prediction algorithms for identifying novel B cell epitopes. Epitope discovery methods may include basic studies in appropriate animal models, but human samples will be required to validate each epitope as a target of antibody-mediated protective or pathogenic immunity and understand the mechanisms by which the antibodies induce protection or pathogenesis. Supported investigators will be required to attend an annual program review meeting at NIH and submit their epitope information to the Immune Epitope Database and Analysis Resource and structural data, if applicable, to a publicly accessible database.

Contracts awarded in fiscal year (FY) 2009 and FY 2014 have been productive, and several changes are anticipated for the FY 2019 renewal. For this recompetition, NIAID will continue to support the study of novel B cell epitopes derived from pathogenic organisms or vaccines against them and mechanisms of antibody-mediated protection associated with these epitopes. The renewed solicitation will eliminate the requirement to select pathogens from the NIAID Priority Pathogens list. NIAID is also expanding the scope of this program to include B cell epitope discovery and mechanisms of antibody-mediated protection or pathogenesis in human autoimmune diseases, and those related to cell/organ/tissue transplant rejection or tolerance.

Large-Scale T Cell Epitope Discovery

For the published broad agency announcement, see the May 8, 2018 solicitation, Large-Scale T Cell Immune Epitope Discovery.

Collaborative Cross Mouse Model Generation and Discovery of Immunoregulatory Mechanisms

For the published program announcement with special receipt, referral, and/or review considerations, see the May 10, 2018 Guide announcement, Collaborative Cross (CC) Mouse Model Generation and Discovery of Immunoregulatory Mechanisms (R21, Clinical Trial Not Allowed).

Immune Mechanisms at the Maternal-Fetal Interface

Request for Applications—proposed FY 2019 initiative

Contact: Mercy PrabhuDas

Objective: To determine the roles and interactions of immune cells at the maternal-fetal interface and their impact on pregnancy outcomes and elucidate the effects of infection or vaccination during pregnancy on these cells and the developing fetal/neonatal immune system.

Description: This initiative will support applications to define immune mechanisms at the maternal-fetal interface that promote a healthy pregnancy, including encounters with commensal organisms, infectious agents, and/or vaccinations. Relevant animal models may be used to study immune interactions during development of the immune system in the fetus. Research supported by this funding opportunity announcement include: mechanisms of inducing, activating, and regulating leukocyte responses and maintaining homeostasis at the maternal-fetal interface; immune pathogenesis of pregnancy complications triggered by infectious and noninfectious etiologies; effect of infection and/or vaccination on the developing fetal immune system; role of immune cells in placental tissue remodeling, blood vessel formation, and/or endometrial stromal cell transformation; epigenetic regulation of immune cell functions during pregnancy; and interactions of the microbiome and immune cells at the maternal-fetal interface. The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) is partnering with NIAID on this initiative. NICHD will support HIV/AIDS studies in the above-defined areas, including effects of HIV infection on fetal immune system development and placental development, and changes after anti-retroviral treatment.

High-Priority Immunology Grants

For more information, see the March 28, 2018 Guide notice, Notice of NIAID's Interest in Continued Support of High-Priority Immunology Grants.

Adjuvant Development for Vaccines and for Autoimmune and Allergic Diseases

Note: NIAID topic for NIH SBIR contract solicitation.

Request for Proposals

Contact: Charles H. Jackson, Jr.

Adjuvant Discovery for Vaccines and for Autoimmune and Allergic Diseases

Note: NIAID topic for NIH SBIR contract solicitation.

Request for Proposals

Contact: Charles H. Jackson, Jr.

B Cell Receptor and T Cell Receptor Repertoire Computational Tools

Note: NIAID topic for NIH SBIR contract solicitation.

Request for Proposals

Contact: Charles H. Jackson, Jr.

Development of Sample Sparing Assays

Note: NIAID topic for NIH SBIR contract solicitation.

Request for Proposals

Contact: Charles H. Jackson, Jr.

Reagents for Immunologic Analysis of Non-Mammalian and Underrepresented Mammalian Models

Note: NIAID topic for NIH SBIR contract solicitation.

Request for Proposals

Contact: Charles H. Jackson, Jr.

Content last reviewed on May 11, 2018